Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory) and compares the effect of tovorafenib and rituximab to current standard treatment of cladribine and rituximab in cHCL patients that have not yet received treatment. Tovorafenib blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cladribine damages the cell's deoxyribonucleic acid and may kill cancer cells. It is a type of antimetabolite. Giving tovorafenib in combination with rituximab may be safe and tolerable and more effective than cladribine with rituximab in treating patients with untreated, recurrent or refractory cHCL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza białaczki włochatek z mutacją genu BRAF
- •Wiek minimum 18 lat
- •Faza 1: Wcześniejsze leczenie lekami podobnymi do puryny (chyba że niemożliwe)
- •Faza 2: Pacjenci bez wcześniejszego leczenia tej choroby
- •Niskie liczby komórek krwi lub objawy wymagające leczenia
- •Dobry ogólny stan zdrowia (ECOG ≤ 2)
- •Prawidłowa funkcja wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
NCI - Center for Cancer Research
Bethesda, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
University of Virginia Cancer Center
Charlottesville, United States
Trial contact
Site Public Contact
Robert J. Kreitman
PRINCIPAL_INVESTIGATOR
Site Public Contact
Seema A. Bhat
PRINCIPAL_INVESTIGATOR
Site Public Contact
Robert L. Redner
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nathan L. Roberts
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.